WallStreetZenWallStreetZen

NASDAQ: AWH
Aspira Women's Health Inc Stock

$4.46+0.05 (+1.13%)
Updated Feb 23, 2024
AWH Price
$4.46
Fair Value Price
N/A
Market Cap
$46.10M
52 Week Low
$2.31
52 Week High
$7.76
P/E
-1.79x
P/B
-69.96x
P/S
5.71x
PEG
N/A
Dividend Yield
N/A
Revenue
$9.18M
Earnings
-$20.91M
Gross Margin
57.6%
Operating Margin
-228.47%
Profit Margin
-227.8%
Debt to Equity
-14.14
Operating Cash Flow
-$18M
Beta
0.95
Next Earnings
Mar 20, 2024
Ex-Dividend
N/A
Next Dividend
N/A

AWH Overview

Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, the company operates Aspira Synergy, a testing platform and cloud service for decentralized access of protein biomarker and hereditary genetic testing; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, its pipeline products include OVAWatch, EndoCheck, and OVAInherit. The company serves physicians, physician office laboratories, and national and regional laboratories. It has a collaborative research agreement with Baylor Genetics; an agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas.

Zen Score

Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AWH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

AWH is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AWH is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
AWH's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more AWH due diligence checks available for Premium users.

Be the first to know about important AWH news, forecast changes, insider trades & much more!

AWH News

Valuation

AWH fair value

Fair Value of AWH stock based on Discounted Cash Flow (DCF)
Price
$4.46
Fair Value
$5.04
Undervalued by
11.44%
AWH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

AWH price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.79x
Industry
39.41x
Market
33.56x

AWH price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-69.96x
Industry
4.29x

AWH's financial health

Profit margin

Revenue
$2.2M
Net Income
-$4.7M
Profit Margin
-212.3%
AWH's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
AWH's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$8.7M
Liabilities
$9.3M
Debt to equity
-14.14
AWH's short-term assets ($7.57M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AWH's short-term assets ($7.57M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AWH's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AWH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$3.3M
Investing
$0.0
Financing
$4.2M
AWH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

AWH vs Diagnostic & Research Stocks

TickerMarket Cap1d %P/EP/B
AWH$46.10M+1.13%-1.79x-69.96x
DMTK$43.49M-2.31%-0.36x0.60x
DRIO$55.25M+0.25%-1.00x0.81x
XGN$34.94M+3.54%-1.10x1.27x
PRE$58.13M0.00%-1.22x0.26x

Aspira Women's Health Stock FAQ

What is Aspira Women's Health's quote symbol?

(NASDAQ: AWH) Aspira Women's Health trades on the NASDAQ under the ticker symbol AWH. Aspira Women's Health stock quotes can also be displayed as NASDAQ: AWH.

If you're new to stock investing, here's how to buy Aspira Women's Health stock.

What is the 52 week high and low for Aspira Women's Health (NASDAQ: AWH)?

(NASDAQ: AWH) Aspira Women's Health's 52-week high was $7.76, and its 52-week low was $2.31. It is currently -42.49% from its 52-week high and 93.16% from its 52-week low.

How much is Aspira Women's Health stock worth today?

(NASDAQ: AWH) Aspira Women's Health currently has 10,336,834 outstanding shares. With Aspira Women's Health stock trading at $4.46 per share, the total value of Aspira Women's Health stock (market capitalization) is $46.10M.

Aspira Women's Health stock was originally listed at a price of $5,353.47 in Oct 2, 2000. If you had invested in Aspira Women's Health stock at $5,353.47, your return over the last 23 years would have been -99.92%, for an annualized return of -26.53% (not including any dividends or dividend reinvestments).

How much is Aspira Women's Health's stock price per share?

(NASDAQ: AWH) Aspira Women's Health stock price per share is $4.46 today (as of Feb 23, 2024).

What is Aspira Women's Health's Market Cap?

(NASDAQ: AWH) Aspira Women's Health's market cap is $46.10M, as of Feb 25, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Aspira Women's Health's market cap is calculated by multiplying AWH's current stock price of $4.46 by AWH's total outstanding shares of 10,336,834.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.